September 2021

In this issue

Complimentary webinars and podcasts, thought-provoking articles, industry news, and more!

Access Full Newsletter

The Altascientist

Mitigate risks with a stepwise approach to first-in-human trials.

Five Ways Altasciences Simplifies the Drug Development Process for You

Discover how Altasciences relieves you of the need to plan and manage the many elements of early phase drug development, for hassle-free outsourcing.  

Benefits of Using Liquid-Filled Capsules in Clinical Trials

Discover why two-piece, liquid-filled, hard-shell capsules (LFCs) are the solution formulation scientists are looking to for turning poorly soluble small molecules into viable development candidates.  

Emyria Limited Partners with Altasciences to Accelerate FDA and TGA CBD Registration

Read this article to learn more about the partnership, which could lead to the first over-the-counter CBD medicine available in Australia. 

Tryp Therapeutics Partners with Altasciences to Conduct Exploratory Studies for Proprietary Psilocybin-Based Formulations

Calvert Labs, an Altasciences Company, has been selected to design and conduct exploratory studies for Tryp’s Psilocybin-for-Neuropsychiatric Disorders (PRNTM) program.

New Podcast Series: “The Many Faces of Recreational Drug Use”

The series is a collection of candid conversations with study participants about their personal drug use history, both with recreational drug use and with substance use disorder. Throughout the conversations, Altasciences’ Dr. Beatrice Setnik, Chief Scientific Officer, and Dr. Debra Kelsh, MD, Senior Principal Investigator and Psychologist, pause to discuss key moments in the interviews. Watch the first episode! 

Alzamend Neuro Contracts Altasciences for Phase I Study of AL001 for Dementia Related to Alzheimer’s Disease

In September, Altasciences began a six-month Phase I relative bioavailability study for AL001 for dementia related to Alzheimer’s disease. The objective of the first-in-human study is to determine the safety, tolerability, and appropriate dosing for future studies. 

Altasciences’ Chief Scientific Officer, Dr. Beatrice Setnik, Contributes to a Study on Difelikefalin

This article for the journal Clinical and Translational Science, co-authored by  Dr. Setnik, shares the findings of a study that assessed the effect of difelikefalin, a selective kappa opioid receptor agonist designed to limit central nervous system (CNS) penetration, on key relevant measures of respiratory depression in healthy volunteers.


  • Webinars
    Catch up on some of our favorite on-demand webinars. 
  • Podcasts
    Listen to (or watch) our discussions on drug development topics, including an interview with Dr. John Atkinson, Founder of Atkinson Toxicology Consulting, the first episode of “The Many Faces of Recreational Drug Use” series, and a discussion on developing the second generation of psychedelics and their analogs for targeted medical use. 
  • Up Close and Personal With…
    Meet Ben Reed, BS, Vice President of Operations for Altasciences’ Manufacturing and Analytical Services. 
  • Blog
    Catch up on Altasciences’ latest blog articles on microsampling, ethnobridging, and liquid-filled capsules.
  • Upcoming Events
    See what events we will be attending over the next few weeks.